PMA Review Timelines: What MDUFA Performance Goals Actually Predict (and What They Don't)

The Gap Between MDUFA Metrics and Real-World PMA Timelines

If you are preparing a Premarket Approval (PMA) application, you have probably looked up FDA's MDUFA performance goals and assumed they tell you how long your review will take. They don't — at least not in the way most founders and regulatory professionals think. Understanding what these metrics actually measure, and where they fall silent, is essential for building a credible development and commercialization timeline.

This post breaks down the mechanics of MDUFA performance goals, what they legitimately predict, and the real drivers of PMA review duration that the metrics simply cannot capture.

What MDUFA Performance Goals Actually Measure

The Medical Device User Fee Amendments, currently operating under MDUFA V (covering fiscal years 2023 through 2027), establish a negotiated set of performance goals between FDA and industry. For original PMAs, the core goal is that FDA will make a substantive decision within 180 days of filing acceptance for a specified percentage of submissions — historically targeting 90% or higher.

A few critical definitions matter here:

• Filing date vs. receipt date: The 180-day clock starts at filing acceptance, not when FDA receives your application. Under 21 CFR 814.42, FDA has 45 days after receipt to make a filing decision. Those 45 days are not counted in the MDUFA goal.
• Substantive decision, not approval: A major deficiency letter, an approvable letter, or a not-approvable letter all count as substantive decisions. The goal measures FDA's responsiveness, not your outcome.
• Clock stops: When FDA issues a major deficiency letter (commonly called an Additional Information, or AI, request), the review clock stops. It restarts only when you respond. Under MDUFA V agreements, FDA targets a 90-day goal to review your AI response — but that is a separate metric from the original 180-day goal.

In practice, a PMA that receives even one major AI request can easily stretch to 300 to 500 total calendar days before a final decision, while still allowing FDA to report 100% compliance with its MDUFA performance goals. The metrics and your actual wait time are measuring two entirely different things.

What MDUFA Goals Genuinely Predict

To be fair, MDUFA performance goals do provide meaningful signals:

• FDA's internal bandwidth: Consistent performance goal achievement indicates the Office of Product Evaluation and Quality (OPEQ) is adequately staffed and managing workloads. When performance begins slipping — as it did in certain quarters during the COVID-19 pandemic — it is an early warning of systemic delay risk across all submissions.
• Baseline planning assumptions: For a well-prepared, complete PMA with no major deficiencies, the 180-day statutory window plus 45 days for filing review gives you roughly a seven-to-eight-month floor for planning purposes. That is a legitimate starting point.
• Comparative device type data: FDA's annual MDUFA performance reports, published on FDA.gov, break down review times by device type and review panel. This data can reveal whether your product category consistently runs at the goal or routinely exceeds it.

What MDUFA Goals Cannot Predict

Here is where most planning models break down. MDUFA metrics are silent on several factors that routinely determine whether a PMA takes eight months or three years:

• Clinical data quality and completeness: A pivotal study that does not cleanly address the predetermined primary endpoint under your FDA-agreed protocol — documented through a Breakthrough Device Designation agreement, Pre-Submission (Q-Sub), or IDE approval — almost guarantees an AI request. No MDUFA metric can tell you whether your clinical package will survive first review.
• Novel technology classification complexity: If your device raises first-of-a-kind safety questions, FDA may convene an advisory panel under 21 CFR 814.44(e). Panel meetings add months and introduce outcome uncertainty that no performance goal reflects.
• Labeling and human factors gaps: Inadequate human factors validation testing, governed by FDA's 2016 guidance 'Applying Human Factors and Usability Engineering to Medical Devices,' is now one of the leading drivers of AI requests in complex device PMAs. This is an entirely submission-quality issue — invisible to MDUFA metrics.
• Manufacturing readiness: FDA's pre-approval inspection (PAI) under 21 CFR 814.44(d) can halt the review clock in ways that do not register in published performance data. A facility that is not inspection-ready when FDA schedules the PAI creates delays the MDUFA framework simply does not capture.
• Reviewer learning curve on novel indications: Reviewer turnover and cross-panel coordination for combination products or diagnostics paired with therapeutics introduce human variability that no negotiated metric accounts for.

Building a Realistic PMA Timeline Model

A defensible PMA timeline is built from the inside out, not from MDUFA benchmarks backward. Start with an honest assessment of your clinical data package, your manufacturing site's inspection readiness, and the completeness of your human factors program. Layer in the MDUFA baseline as a floor, not a ceiling. Add contingency for at least one AI cycle — because statistically, most original PMAs receive one.

Use Pre-Submission meetings aggressively. FDA's Pre-Sub program exists precisely to surface deficiencies before submission. A Pre-Sub that reveals a clinical gap 18 months before PMA filing saves far more time than any MDUFA goal ever could.

The Bottom Line

MDUFA performance goals are a measure of FDA's process discipline — not a predictor of your approval timeline. The variables that actually determine how long your PMA takes live inside your submission: the strength of your clinical evidence, the rigor of your manufacturing quality system, and the completeness of your regulatory strategy from day one.

At ADB Consulting and CRO Inc., we help medical device companies build PMA strategies grounded in regulatory reality — not optimistic benchmarks. If you are planning a PMA submission and want an honest assessment of your timeline risks and submission readiness, book a free discovery call with ADB's regulatory team at adbccro.com. Let's build a strategy that holds up under FDA review.

If this applies to your program, PMA Submission for Class III Devices — End-to-End Prep walks through the process in detail.